MedPage Today -- TORONTO -- Rituximab (Rituxan), the anti-CD20 antibody that decreases B-cell activation, slashed autoantibody titers and improved symptoms in patients with myasthenia gravis (MG) refractory to standard therapies, a researcher said here.
